Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $1,505,494.98 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 235,971 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $6.38, for a total transaction of $1,505,494.98. Following the completion of the sale, the insider owned 14,110,209 shares of the company’s stock, valued at approximately $90,023,133.42. The trade was a 1.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Monday, November 24th, Endurance (Cayman) Ltd Svf sold 227,803 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total transaction of $1,400,988.45.
• On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.49, for a total value of $649.00.
• On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.50, for a total value of $158,944.50.
• On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total transaction of $401,738.15.
• On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.96, for a total value of $278,308.16.
• On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.99, for a total value of $924,754.17.
• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total transaction of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.30, for a total transaction of $690,952.50.
• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.20, for a total transaction of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total transaction of $78,348.40.

Vir Biotechnology Stock Down 0.8%

VIR stock traded down $0.05 during trading on Wednesday, hitting $6.39. The company had a trading volume of 1,892,329 shares, compared to its average volume of 1,543,817. The firm has a 50-day moving average price of $5.68 and a 200-day moving average price of $5.27. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $14.45. The stock has a market cap of $888.98 million, a price-to-earnings ratio of -1.77 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.47). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $1.98 million. Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. The firm’s quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the business posted ($1.56) earnings per share. Equities analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new stake in Vir Biotechnology in the 2nd quarter valued at $35,000. Federated Hermes Inc. raised its stake in shares of Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after purchasing an additional 4,899 shares during the period. Apollon Wealth Management LLC acquired a new stake in shares of Vir Biotechnology in the second quarter valued at approximately $50,000. Daiwa Securities Group Inc. lifted its position in shares of Vir Biotechnology by 2,200.6% in the second quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock worth $62,000 after purchasing an additional 11,773 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Vir Biotechnology during the second quarter worth $63,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on VIR shares. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Monday, September 15th. Evercore ISI initiated coverage on shares of Vir Biotechnology in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price objective on the stock. Bank of America raised shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and raised their price objective for the company from $12.00 to $14.00 in a research note on Wednesday, August 27th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Vir Biotechnology in a research note on Monday. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.30.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).